![Harry Raftopoulos](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
Harry Raftopoulos is Senior Vice President & Clinical Research at Eikon Therapeutics, Inc. since 2023.
Formerly, Mr. Raftopoulos was a Scientific Advisor at FutuRx Ltd.
Harry Raftopoulos active positions
| Companies | Position | Start |
|---|---|---|
| EIKON THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2023 |
Former positions of Harry Raftopoulos
| Companies | Position | End |
|---|---|---|
FutuRx Ltd.
 FutuRx Ltd. Investment ManagersFinance FutuRx invests in companies located in Israel. The firm focuses on sectors such as health technology and technology services with an investment size of ILS 3 million. It participates in seed stage transactions and also makes follow on investment. | Consultant / Advisor | 01/04/2023 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx invests in companies located in Israel. The firm focuses on sectors such as health technology and technology services with an investment size of ILS 3 million. It participates in seed stage transactions and also makes follow on investment. | Finance |
Eikon Therapeutics, Inc.
 Eikon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical biopharmaceutical and drug discovery company | Health Technology |
- Stock Market
- Insiders
- Harry Raftopoulos
